Wall Street brokerages predict that Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) will post ($0.25) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Spring Bank Pharmaceuticals’ earnings. Spring Bank Pharmaceuticals posted earnings of ($0.42) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 40.5%. The business is scheduled to issue its next earnings report on Thursday, November 5th.
According to Zacks, analysts expect that Spring Bank Pharmaceuticals will report full-year earnings of ($1.40) per share for the current financial year. For the next year, analysts forecast that the firm will post earnings of ($0.79) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that follow Spring Bank Pharmaceuticals.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.02).
A hedge fund recently raised its stake in Spring Bank Pharmaceuticals stock. JPMorgan Chase & Co. grew its stake in shares of Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) by 190.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 49,492 shares of the company’s stock after buying an additional 32,471 shares during the quarter. JPMorgan Chase & Co. owned about 0.29% of Spring Bank Pharmaceuticals worth $46,000 as of its most recent filing with the Securities and Exchange Commission. 17.17% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:SBPH traded up $0.01 during mid-day trading on Monday, hitting $1.39. The stock had a trading volume of 17,656 shares, compared to its average volume of 192,257. The stock has a market capitalization of $24.01 million, a price-to-earnings ratio of -0.80 and a beta of 1.13. The company has a 50 day simple moving average of $1.36 and a 200-day simple moving average of $1.45. Spring Bank Pharmaceuticals has a 52 week low of $0.80 and a 52 week high of $4.80. The company has a current ratio of 5.11, a quick ratio of 5.11 and a debt-to-equity ratio of 0.12.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules.
Featured Article: What are trading strategies for the 52-week high/low?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.